For those patients intolerant to platinum-containing regimen, platinum-free double-agent chemotherapy regimens are used as an alternative. For those patients with ECOG score as 2 or the elderly patients, single-agent or double-agent regimens are recommended. The chemotherapy of cisplatin plus vinorelbine may recombine human endostatin. China has approved that single-agent gefitinib may be used in first-line treatment of locally advanced or metastatic NSCLC patients with sensitive mutation of epidermal growth factor receptor tyrosine kinase gene.